“Efficacy and safety outcomes from the MATISSE phase 3 trial of maternal bivalent RSVpreF vaccination among pregnant women vaccinated at 32 to 36 weeks of gestation”, Swiss Med Wkly, vol. 156, no. 1, p. 4711, Jan. 2026, doi: 10.57187/4711.